Journal Article

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study

Graham, Peter H, Vu, T Trinh T, Olivotto, Ivo A, Martin, Joseph D, Gruber, Guenther, Muanza, Thierry M, Harvey, Jennifer A, Chua, Boon H, Westenberg, A Helen, Bryant, Guy, Link, Emma K, Akra, Mohamed, McArdle, Orla, Neal, Anthony, Kunkler, Ian H, Delaney, Geoff P, Whelan, Timothy J, Purohit, Kash, Campbell, Ian D, Maduro, John H, Ahern, Verity, O'Brien, Peter, Kirkove, Carine

2022

Overview

Whole breast irradiation (WBI) after conservative surgery for ductal carcinoma in situ (DCIS) reduces local recurrence. We investigated whether a tumour bed boost after WBI improved outcomes, and examined radiation dose fractionation sensitivity for non-low-risk DCIS. The study was an international, randomised, unmasked, phase 3 trial involving 136 participating centres of six clinical trials organisations in 11 countries (Australia, New Zealand, Singapore, Canada, the Netherlands, Belgium, France, Switzerland, Italy, Ireland, and the UK). Eligible patients were women aged 18 years or older with unilateral, histologically proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial resection margins. They were assigned to one of four groups (1:1:1:1) of no tumour bed boost versus boost after conventional versus hypofractionated WBI, or randomly assigned to one of two groups (1:1) of no boost versus boost after each centre prespecified conventional or hypofractionated WBI. The conventional WBI used was 50 Gy in 25 fractions, and hypofractionated WBI was 42·5 Gy in 16 fractions. A boost dose of 16 Gy in eight fractions, if allocated, was delivered after WBI. Patients and clinicians were not masked to treatment allocation. The primary endpoint was time to local recurrence. This trial is registered with ClinicalTrials.gov (NCT00470236). Between June 25, 2007, and June 30, 2014, 1608 patients were randomly assigned to have no boost (805 patients) or boost (803 patients). Conventional WBI was given to 831 patients, and hypofractionated WBI was given to 777 patients. Median follow-up was 6·6 years. The 5-year free-from-local-recurrence rates were 92·7% (95% CI 90·6–94·4%) in the no-boost group and 97·1% (95·6–98·1%) in the boost group (hazard ratio 0·47; 0·31–0·72; p<0·001). The boost group had higher rates of grade 2 or higher breast pain (10% [8–12%] vs 14% [12–17%], p=0·003) and induration (6% [5–8%] vs 14% [11–16%], p<0·001). In patients with resected non-low-risk DCIS, a tumour bed boost after WBI reduced local recurrence with an increase in grade 2 or greater toxicity. The results provide the first randomised trial data to support the use of boost radiation after postoperative WBI in these patients to improve local control. The international scale of the study supports the generalisability of the results. National Health and Medical Research Council of Australia, Susan G Komen for the Cure, Breast Cancer Now, OncoSuisse, Dutch Cancer Society, Canadian Cancer Trials Group.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Breast cancer / Breast Neoplasms - etiology / Breast Neoplasms - radiotherapy / Breast Neoplasms - surgery / Canada / Cancer therapies / Carcinoma, Intraductal, Noninfiltrating - radiotherapy / Carcinoma, Intraductal, Noninfiltrating - surgery / Clinical trials / Dose Fractionation, Radiation / Endocrine therapy / Ethics / Female / Fractionation / Health care access / Humans / Irradiation / Lumpectomy / Mastectomy, Segmental / Medical research / Neoplasm Recurrence, Local - etiology / Neoplasm Staging / Pain / Patients / Quality of life / Radiation / Radiation Dosage / Radiation therapy / Review boards / Risk / Surgery / Toxicity / Tumors / Womens health